Inovio Pharmaceuticals, Inc.
INO
$2.02
$0.105.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.18% | -9.75% | |||
| Gross Profit | 8.18% | 9.39% | |||
| SG&A Expenses | -8.01% | -5.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.12% | -8.09% | |||
| Operating Income | 8.12% | 7.85% | |||
| Income Before Tax | -93.44% | -19.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -93.44% | -19.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -93.44% | -19.42% | |||
| EBIT | 8.12% | 7.85% | |||
| EBITDA | 8.22% | 7.90% | |||
| EPS Basic | -43.98% | -18.76% | |||
| Normalized Basic EPS | -43.73% | -18.19% | |||
| EPS Diluted | -43.98% | -18.76% | |||
| Normalized Diluted EPS | -43.73% | -18.19% | |||
| Average Basic Shares Outstanding | 34.35% | 0.56% | |||
| Average Diluted Shares Outstanding | 34.35% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||